| DRUG WATCH |
|
| Year : 2021 | Volume
: 53
| Issue : 3 | Page : 229-233 |
The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: A short-term observational study
Jithin Chacko1, Shankar Dhandapani2, Vidhya Jahagiridhar2, Krishnan Swaminathan3
1 Department of Pharmacology, KMCH College of Pharmacology, Coimbatore, Tamil Nadu, India
2 Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital, Coimbatore, Tamil Nadu, India
3 Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital; KMCH Research Foundation, Coimbatore, Tamil Nadu, India
Correspondence Address:
Dr. Krishnan Swaminathan
Department of Diabetes and Endocrinology, Kovai Medical Center and Hospital, Coimbatore - 641 014, Tamil Nadu
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijp.IJP_669_18
The aim of this study was to assess the short-term cardiometabolic outcomes in type 2 diabetes patients receiving empagliflozin in a tertiary referral center. Three hundred and fifteen consecutive patients started on empagliflozin were followed for a 4-month period after local ethics committee approval for a range of outcomes. Data were recorded on Microsoft Excel and transposed to SPSS for further analysis. Empagliflozin treatment resulted in statistically significant reductions in weight, glycosylated hemoglobin, and systolic and diastolic blood pressures along with favorable lipid profile outcomes over a 4-month period. The rates of discontinuation of the medications due to genomycotic infections were extremely low at 0.6% with no episodes of severe hypoglycemia or euglycemic diabetic ketoacidosis. Empagliflozin therapy, either in addition to other oral agents or insulin, seems to result in favorable outcomes in cardiometabolic risk factors in the immediate short term. Long-term follow-up of this cohort will shed light on cardiovascular outcomes and adverse effects in our population in real-world clinical practice.
[FULL TEXT] [PDF]*
|
